Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations

10 Jun 2019

Abstract excerpt

Compared to solid tumors, the role of PD-L1 in hematological malignancies is less explored, and the knowledge in this area is mostly limited to lymphomas. However, several studies indicated that PD-L1 is also overexpressed in myeloid malignancies. Successful treatment of the acute myeloid leukemia (AML) is likely associated with elimination of the residual disease by the immune system, and possible involvement of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer Immunotherapy and Biomarkers
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31185600
DOI: 10.3390/ijms20112823

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 MutationsPMID 31185600Read ↗

Correlation of PD-L1 Surface Expression on Leukemia Cells with the Ratio of PD-L1 mRNA Variants and with Electrophoretic Mobility.Semantic proximity Read ↗

PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathwaySemantic proximity Read ↗

Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.Semantic proximity Read ↗

Immunotherapeutic Potential of Mutated NPM1 for the Treatment of AMLSemantic proximity Read ↗

Cellular expression of PD-1, PD-L1 and CTLA-4 in patients with JAK2V617F mutated myeloproliferative disorders.Semantic proximity Read ↗

Programmed death-ligand 1 expression in patients with primary or secondary myelofibrosis.Semantic proximity Read ↗

Programmed Death-Ligand 1 (PD-L1) Expression in Patients with Primary or Secondary MyelofibrosisSemantic proximity Read ↗

The role of NPM1 alternative splicing in patients with chronic lymphocytic leukemia.Semantic proximity Read ↗

miR-21 is overexpressed in NPM1-mutant acute myeloid leukemias.Semantic proximity Read ↗

Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.Semantic proximity Read ↗

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)Semantic proximity Read ↗

[Expression and clinical significance of PDCD5 in patients with acute myeloid leukemia].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.